Current perspectives on KMT2A fusion proteins and menin inhibition in paediatric acute myeloid leukaemia.

Abbreviations

daunorubicin and cytarabine standard‐of‐care chemotherapy combination

acute leukaemia

acute lymphoid leukaemia

acute myeloid leukaemia

B‐Cell Lymphoma‐2

B‐lymphoma Mo‐MLV Insertion region 1

chronic lymphoid leukaemia

complete remission

composite complete remission defined as CR or CR with partial or incomplete haematological recovery

complete remission with partial haematological recovery

C‐terminal Binding Protein

Cyclophilin 33

diffuse large B‐cell lymphoma

fludarabine and cytarabine

fludarabine, cytarabine, granulocyte‐colony stimulating factor, and idarubicin

FMS‐Like Tyrosine kinase 3

mutant FMS‐Like Tyrosine kinase 3

FY‐rich N‐terminal

FY‐rich C‐terminal

gemtuzumab ozogamicin

histone H3 lysine 27 tri‐methylation

histone H3 lysine 4 tri‐methylation

histone H3 lysine 79

hyper‐cyclophosphamide, vincristine and dacarbazine chemotherapy

haematopoietic cell transplant

Histone deacetylase

Homeobox

Histone Promoter Control 2

Human Genome Organisation

lysine methyltransferase 2A (rearranged/rearrangements)

lysine methyltransferase 2C

low‐dose cytarabine

Lens Epithelium‐Derived Growth Factor

Methyl‐Binding Domain

Mixed Lineage Leukaemia protein 1

multiple myeloma

Mixed Phenotype Acute Leukaemia

Multiple Endocrine Neoplasia, type 1

Myeloid Ecotropic viral Integration Site 1 homologue

newly diagnosed

nucleophosmin 1

mutant nucleophosmin 1

Nuclear Pore complex 214 (rearrangements)

Nuclear Pore complex 98 (rearrangements)

overall response rate

Polymerase‐Associated Factor (1 complex)

Plant Homeodomain

patients

relapsed/refractory

Su(var)3–9, Enhancer‐of‐zeste, and Trithorax

Super Elongation Complex

Therapeutically Applicable Research to Generate Effective Treatments

Upstream Binding Transcription Factor (tandem duplications)

venetoclax/azacytidine

Introduction

Acute myeloid leukaemia (AML) is a molecularly heterogeneous cancer of the bone marrow and peripheral blood that is characterised by the (oligo−/multi‐)clonal proliferation of undifferentiated myeloid blasts or progenitor cells [ 1 , 2 ]. It tends to be viewed as a disease of the elderly; however, it can develop in children, sometimes as early as a few days after birth [ 3 ] or even in utero , as translocations have been observed on Newborn Screen/Guthrie test blood spots [ 4 ]. Despite some advances in therapeutic options, AML remains difficult to treat. This is particularly the case in very young patients with increased susceptibility to therapy‐related toxicity [ 5 ]. Fortunately, collaborative efforts are already in place to better understand the biology of several high‐risk or hard‐to‐treat paediatric cancers. One of which is the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. A landmark study from their AML project involved genomic analyses of nearly 1000 children and young adults with AML and revealed that the disease differs greatly between younger and older patients, at the genetic level. Specifically, somatic mutations are much more common in older adults with AML, whereas structural alterations are more abundant in younger patients with the disease [ 6 ]. A substantial proportion of the structural alterations are due to translocations, where sections of chromosomes shift, and can result in the production of fusion genes and fusion proteins. Indeed, rearrangements involving chromosome band 11q23 and KMT2A ( KMT2A r) are key drivers of acute leukaemias—representing about 15% of paediatric AML cases [ 7 ]—and a defining genetic abnormality used by the World Health Organization to help classify AML [ 8 ]. These patients often present with high‐risk clinical characteristics, including elevated white blood cell counts and extramedullary involvement [ 9 ].

NB: Human Genome Organisation (HUGO) nomenclature ( https://www.genenames.org/ ) is utilised throughout the text, with some genes along with their former synonyms listed here for convenience: KMT2A = former MLL , AFF1 = former AF4 , MLLT1 = former ENL , MLLT3 = former AF9 , AFDN = former AF6 , MLLT10 = former AF10 , MLLT11 = former AF1Q .

KMT2A structure and function

KMT2A , or MLL1 as it was previously known, encodes a histone H3 lysine 4 methyltransferase which plays a crucial role in regulating gene expression during embryonal development and the maintenance of haematopoietic stem cells [ 10 ]. The KMT2A protein is processed by the endopeptidase, Taspase1, into two amino (N320) and carboxyl (C180) terminal fragments [ 11 ], which reassociate (via their FYRN and FYRC domains) to form a molecular hub for the assembly of larger multiprotein complexes in the nucleus (Fig. 1 ). Simply put, the N‐terminal portion of KMT2A is responsible for promoter binding and reading of chromatin signatures, while the C‐terminal portion—which contains a Su(var)3–9, Enhancer‐of‐zeste and Trithorax (SET) domain—methylates lysine 4 within histone H3 to promote the transcription of target genes, including HOX genes [ 12 , 13 ] (Fig. 1 ). It is worth noting that transcriptional profiling of isogenic wildtype and KMT2A knockout murine fibroblasts revealed that more genes were upregulated than downregulated in the knockout situation, suggesting the presence of a molecular switch that toggles between transcriptional activation and repression [ 14 ]. We now know that this is due to a conformational change following CYP33—a prolyl‐peptidyl isomerase—binding to the enhanced plant homeodomain 3 (ePHD3) subdomain within KMT2A. Typically, ePHD3 binds to di‐ and tri‐methylated lysine‐4 residues within histone H3 [ 15 ]. However, CYP33‐mediated cis‐trans isomerisation of the proline‐1665 residue in KMT2A prevents this and instead enables the subsequent recruitment of a polycomb repressor complex (i.e. BMI1, HPC2, CtBP and HDAC1/2) to the methyl‐DNA binding domain (MBD) of KMT2A [ 16 ] (Fig. 2 ). The distinct domains within KMT2A which we are still learning more about [ 17 ], along with the various proteins and transcription factors that contribute to the functional KMT2A multiprotein complex, are crucial for regulating target genes during embryonic haematopoietic stem cell development [ 18 ] and adult haematopoiesis [ 10 ].

Given the subtle but fundamental roles of wildtype KMT2A in haematopoiesis, it is no surprise that genetic rearrangements resulting in the expression of KMT2A fusion alleles can lead to dramatic transcriptional disturbances that contribute to the onset of acute leukaemias. Indeed, aberrant H3K79 methylation profiles [ 19 ] and upregulated HOXA / MEIS1 gene signatures [ 20 ] are hallmark features and well‐established pathomechanisms of KMT2Ar acute leukaemias. While KMT2A rearrangements affect the vast majority (≥ 70%) of infant acute lymphoblastic leukaemia (ALL) cases and a substantial proportion of adult cases, KMT2Ar ALL is beyond the scope of this article, and interested readers are instead directed to [ 21 , 22 , 23 ] for further information.

Chromosomal translocations involving human KMT2A ( NM_001412597.1 ) and 112 partner genes have been identified so far [ 17 ]. However, the majority of recurrent KMT2A r leukaemic translocations involve relatively few fusion partner genes. For instance, ~ 80.7% of cases in a paediatric cohort of 1256 patients with KMT2Ar AML were characterised by six fusion genes, including KMT2A::MLLT3 / t (9;11) (p22; q23) (43.3%), KMT2A::MLLT10 / t (10;11) (p12; q23) (17.4%), KMT2A::AFDN / t (6;11) (q27; q23) (7.3%), KMT2A::ELL / t (11; 19) (q23; p13.1) (6.0%), KMT2A::MLLT1 / t (11; 19) (q23; p13.3) (4.5%) and KMT2A::MLLT11 t (1; 11) (q21; q23) (2.2%) [ 24 ]. Interestingly, four of these partner proteins (i.e. MLLT3/AF9, MLLT10/AF10, ELL and MLLT1/ENL) are involved in transcriptional elongation, as they either bind directly or indirectly—via Super Elongation Complexes (SEC)—to RNA polymerase II [ 25 , 26 , 27 , 28 ].

With such a comprehensive list of KMT2A fusion partners, two key concepts emerge—what are the molecular consequences of KMT2A translocations and how important are the contributions of the different fusion partners to the underlying cancer biology of KMT2Ar AML?

With regards to the first point, KMT2A rearrangements usually result in physical separation of the MBD from downstream plant homeodomain (PHD) regions, resulting in loss of the intrinsic control mechanism of the KMT2A protein and separating its epigenetic reading and writing functions. Consequently, both separated portions of KMT2A become constitutively active, regardless of their fused protein sequences. The direct KMT2A‐X fusions still bind via menin/LEDGF and the PAF complex to chromatin but are incapable of transcriptional repression as they lack the necessary PHDs (Fig. 2 ). This was effectively demonstrated by the artificial fusion of PHD to existing KMT2A‐X proteins, which then enabled the subsequent recruitment of the polycomb repressor complex and eliminated the oncogenic properties of the KMT2A‐X fusion proteins [ 29 , 30 ]. Reciprocal X‐KMT2A fusion proteins which retain their ePHD3 chromatin reader and SET domain are unable to bind the polycomb repressor complex, regardless of CYP33 binding, due to loss of the MBD (Fig. 2 ). This is not dissimilar to other chromosomal translocations, such as the oncogenic BCR‐ABL1 translocation in chronic myeloid leukaemia which destroys an intrinsic control mechanism within the ABL kinase, producing a constitutively active BCR‐ABL1 fusion protein [ 31 ].

Delving beyond the physical separation of the MBD and PHD, the KMT2A gene contains a major breakpoint cluster region (BCR1) between intron 7 and exon 13, and a minor BCR (BCR2) located further downstream between exons 21 and 25. Interestingly, while breakpoints in ALL patients are found in both regions, AML breakpoints seem to exclusively occur in BCR1 [ 32 ]. The focus on KMT2A breakpoint distribution stems from correlations with the outcome of KMT2Ar leukaemia patients. More specifically, breakpoints within exon 11 or intron 11 of KMT2A are typically associated with poorer clinical outcomes [ 33 ]. This is because these breakpoints can alter or destroy the structure of the cysteine‐histidine‐rich PHD1‐3 domain thereby compromising its associated functions, which can: (a) limit functional dimerisation [ 34 ]; (b) enhance the stability of KMT2A fusion proteins by interfering with the binding of CDC34 (to PHD2) [ 35 ] or ECS ASB2 [ 36 ], thereby rendering them resistant to proteasomal degradation; and (c) impair CYP33 binding leading to loss of the transcriptional repressor activity of KMT2A [ 37 ]. While AML patient breakpoints exhibit a preferential KMT2A intron 9 breakage which decreases slightly with age, further analysis of breakpoint localisation within subregions of BCR1 (i.e. exon9‐intron10 and exon11‐exon13), revealed that certain fusion genes have selective breakpoint preferences (which probably has something to do with the respective functions of the fusion partners) and that these breakpoint tendencies also seemed to change with age [ 32 ]. For example, KMT2A::AFF1 and KMT2A::ELL patients exhibit opposite predispositions, that is infant KMT2A::AFF1 patient breakpoints predominantly localise to intron 11, while adult KMT2A::AFF1 patient breakpoints shift to introns 9 and 10; whereas infant KMT2A::ELL patients have a preference for intron 9 breakpoints, while paediatric and adult KMT2A::ELL patient breakpoints shift towards intron 11 [ 32 ].

Analysis of large cohorts of patients with integrated molecular data suggests that KMT2A fusion partners carry prognostic significance. For instance, KMT2A::MLLT3 and KMT2A::MLLT11 tend to be associated with more favourable survival outcomes in children, whereas KMT2A::MLLT10 and KMT2A::AFDN are among the KMT2A rearrangements with the poorest prognoses in children [ 38 ]. Furthermore, KMT2A::MLLT3 is categorised as intermediate risk according to the 2022 edition of the European Leukaemia Net recommendations, with other KMT2Ar associated with less favourable outlooks [ 39 ]. Although it should be noted that the prognosis of children with KMT2A::MLLT3 can be adversely affected by the presence of secondary chromosome aberrations [ 24 , 40 ] and/or by a marrow morphology that is different from acute monoblastic leukaemia (FAB‐M5) [ 38 ]. In a similar vein, more recent evidence suggests that the aforementioned favourable risk stratification of KMT2A::MLLT11 should be revised to intermediate risk [ 24 ]. A retrospective international study of 1130 paediatric KMT2Ar AML patients categorised cases with KMT2A::MLLT10 , KMT2A::AFDN , KMT2A::MLLT1 , KMT2A::AFF1 / t (4; 11) (q21; q23), and KMT2A::ABI1 / t (10; 11) (p11.2; q23) rearrangements as high risk, with remaining cases allocated to a non‐high risk group [ 9 ]. The high‐risk cohort exhibited a higher cumulative incidence of relapse (59.7% for high risk vs 35.2% for non‐high risk; P < 0.0001), lower event‐free survival (EFS) rates (30.3% vs 54.0%; P < 0.0001), and worse overall survival (OS) (49.2% vs 70.5%; P < 0.0001) [ 9 ].

The remaining list of recurrently diagnosed translocation partner genes is long, but these cases are rare and not of pressing clinical relevance. However, they should not be overlooked and a systemic classification about their functions has already been proposed [ 41 ]. The presence of reciprocal X‐KMT2A fusion proteins is yet another important factor, as demonstrated by the chromatin opening capability of AFDN::KMT2A and its ~ 12‐fold enhancement of the KMT2Ar transcriptome [ 42 ]. Gene dysregulation of this magnitude likely contributes to the onset of pre‐leukaemic clones that then undergo selection to overt leukaemic cells. However, the enhanced transcriptome could also result in the expression of more druggable target proteins that may sensitise the leukaemic cells, ultimately translating to better clinical outcomes. It is possible that leukaemic cells lacking a reciprocal fusion protein and therefore possessing a more restricted transcriptome, might be more chemo‐resistant. As such, the identification of reciprocal fusion proteins could provide important prognostic information and impact disease monitoring.

Current and future therapies involving menin inhibition

Children with KMT2Ar AML are associated with an intermediate 5‐year event‐free survival rate of ~ 45% and an overall survival rate of ~ 63%, highlighting an unmet clinical need for this patient population [ 9 ]. At present, strategies to treat KMT2Ar leukaemias are based on canonical risk stratification [ 39 ], although menin inhibition has emerged as a promising new class of targeted therapy for KMT2Ar AML [ 2 ].

Biological basis for menin inhibition

Menin is a chromatin adaptor protein, encoded by the MEN1 gene, that participates in epigenetic gene regulation through its interactions with various proteins—including chromatin modifying proteins and transcription factors [ 43 ]. It has paradoxical roles, acting as both a tumour suppressor and an oncogenic co‐factor, depending on the cellular context. Mutations in the MEN1 gene that disrupt its functionality are typically associated with Multiple Endocrine Neoplasia Type 1 (MEN1) syndrome [ 44 , 45 ], highlighting the tumour suppressive activity of the gene in neuroendocrine tissues. In contrast, menin serves as an oncogenic co‐factor in haematopoietic pathological states [ 46 ]. Indeed, menin was initially identified as an essential oncogenic co‐factor for KMT2Ar leukemogenesis in a mouse model back in 2005 [ 47 ]. Since then, there has been considerable development into several iterations of highly selective small molecule menin inhibitors (summarised in Table 1 ), with eight compounds currently at various clinical stages for the treatment of AML: ziftomenib (KO‐539), revumenib (SNDX‐5613), bleximenib (JNJ‐75276617), BN104, icovamenib (BMF‐219), DS‐1549, enzomenib (DSP‐5336) and balamenib (ZE63‐0302) (summarised in Table 2 ). The MEN1 inhibitor (or MI) class of drugs (listed in Table 1 ) has culminated in the commercially available ziftomenib, whereas the preclinical precursor VTP‐50469 has led to revumenib which is currently the only FDA‐approved menin inhibitor for the treatment of relapsed/refractory (R/R) AML [ 48 ]. With a generally favourable safety profile in patients, most of the adverse effects associated with these agents are manageable and reversible through dose adjustments and supportive care [ 2 ].

These compounds work by specifically targeting a central hydrophobic pocket on menin's surface to prevent the protein–protein interaction between menin and KMT2A (i.e., either the N‐terminal portion of wildtype KMT2A or oncogenic fused versions of the protein) [ 49 ]. This effectively inhibits KMT2A‐dependent transcription of downstream target genes, thereby blocking an important component in the pathogenesis of KMT2Ar AML. Importantly, the first two menin inhibitors taken forward for in vivo work—MI‐463 and MI‐503—blocked the progression of KMT2Ar AML in mice, without impairing normal haematopoiesis [ 50 ]. Furthermore, another study found that treatment of KMT2Ar AML cell lines with the same two menin inhibitors led to increased ubiquitylation and reduced protein stability of menin, suggesting an additional aspect of menin inhibition beyond physical disruption of the menin‐KMT2A interaction [ 51 ]. Leaning into this theme, recent work has demonstrated altered gene expression following menin inhibition, beyond the typical silencing of the HOX ‐ and MEIS1 ‐dependent oncogenic transcriptional programme. For instance, menin loss (via genetic knockout and VTP‐50469 treatment) resulted in redistribution of KMT2A from (menin‐dependent) active genes to a subset of silent bivalent genes (i.e. genes which are concurrently marked by activating H3K4me3 and repressive H3K27me3 modifications to maintain a transcriptionally inert state, poised for activation or stable repression), which elevated menin‐independent KMT2A gene expression [ 52 ]. Moreover, these upregulated genes included major histocompatibility class I (MHC‐I) molecules, suggesting that the efficacy of menin inhibition may involve the loss of immune evasion in KMT2Ar leukaemic blasts [ 52 ]. Additional supporting evidence comes from a recent study demonstrating bleximenib‐induced ( MEIS1 ‐independent) upregulation of HLA class I and II expression in leukaemic blasts, along with enhanced T‐cell mediated cytotoxicity [ 53 ].

In summary, the anti‐leukaemic effects of menin inhibitors can be achieved through both canonical and non‐canonical mechanisms, via disruption of leukaemogenic transcriptional programs while also reshaping the immunogenic landscape of KMT2Ar AML. As such, menin inhibition remains a promising therapeutic strategy with potential to directly suppress leukaemic proliferation and enhance immune‐mediated clearance of leukaemic cells.

Challenges and resistance mechanisms

Menin inhibitors have great potential for addressing unmet needs in various subtypes of genetically defined acute leukaemias, typically characterised by (menin‐dependent) upregulation of HOX gene expression [ 54 ]. However, enrolling paediatric patients in clinical trials is challenging, mainly due to the small number of affected individuals. The annual incidence of newly diagnosed paediatric AML cases globally is fewer than 1000, with an estimated annual incidence of around 350 cases of newly diagnosed and recurrent KMT2Ar AML among paediatric patients [ 55 ]. Without global collaboration, these limitations can impede insights into side effects and efficacy across KMT2A fusion partners.

Drug resistance is a recurring theme in the development of cancer treatments, and menin inhibition is no exception. Two forms of menin inhibitor resistance have been described: MEN1 mutations and non‐ MEN1 mutation‐driven mechanisms for example through cellular adaptation processes. In the case of the former, somatic MEN1 mutations were identified in patients that received revumenib (38.7% in the AUGMENT‐101 phase 1 trial), as well as in patient‐derived xenograft models and an unbiased base‐editor screen [ 56 ]. Some of these mutations (including M327I, G331D, G331R and T349M) affect residues near the KMT2A binding site in menin, generating steric hindrance with revumenib to effectively attenuate binding of the inhibitor with menin, but without impacting the menin‐KMT2A interaction [ 57 ]. The G331D mutation is particularly interesting as it results in a very slow dissociation of KMT2A from menin, suggesting that the menin G133D ‐KMT2A interaction might be even more challenging to dissociate with small molecule inhibitors, when compared to wildtype and other mutant versions of menin [ 57 ].

Menin inhibitor resistance arising in the absence of MEN1 mutations is much broader, ranging from alterations in parallel or downstream pathways [ 58 , 59 ] to treatment‐induced clonal evolution despite on‐target efficacy of inhibitors at the transcriptional level [ 60 , 61 ]. Delving deeper into the altered signalling pathways, loss of non‐canonical polycomb repressive complex 1.1 (PRC1.1)‐mediated signalling has been linked with menin inhibitor resistance, via epigenetic reactivation of non‐canonical menin‐KMT2A targets, such as MYC [ 58 ]. This is problematic because MYC is a critical oncogene that has been implicated in AML pathogenesis [ 62 ] and the promotion of cytotoxic drug resistance [ 63 ]. Moreover, after establishing that the UTX‐KMT2C/D complex contributes to the efficacy of menin inhibition by inducing a myeloid differentiation program, a patient‐derived xenograft model of AML harbouring a KMT2C mutation was found to be resistant to VTP‐50469 [ 59 ]. This effectively highlights acquired mutagenesis of essential, non‐driver epigenetic regulators as potential adaptive pathways contributing towards menin inhibitor resistance.

Strategies to mitigate resistance

Some of the MEN1 mutations (i.e. M327I and T349M) that confer resistance to revumenib could potentially be addressed with newer iterations of menin inhibitors, such as bleximenib (JNJ‐75276617) [ 64 ] and balamenib (ZE63‐0302) [ 65 ] which circumvent the acquired steric hindrance through a unique binding mode. With this in mind, it seems prudent to standardise MEN1 mutation status monitoring during menin inhibition therapy, as this could help guide treatment decisions and ultimately improve patient outcomes.

Combination treatments with menin inhibitors are also being pursued both in preclinical studies (Table 3 ) and clinical trials (Table 2 ) to either prevent or overcome intrinsic and acquired mechanisms of resistance.

While KMT2Ar AML typically has a lower incidence of co‐existing gene mutations, a number of tyrosine kinase‐PI3K‐RAS pathway mutations ( FLT3, NRAS , KRAS , PTPN11 and BRAF ) have been reported to co‐occur and confer more aggressive, high‐risk leukaemic profiles [ 66 , 67 ], presumably by promoting the clonal expansion of KMT2Ar leukaemic cells, as demonstrated in a retroviral AML mouse model [ 68 ]. Although resistance to menin inhibitors in these unfavourable AML subsets hasn't yet been described per se , combination therapies with menin and FLT3 or MEK inhibitors (which target the RAS/MAPK pathway) are already underway in clinical (Table 2 ) and preclinical [ 69 ] (Table 3 ) settings.

The rationale for combining menin inhibition with broadly effective agents (e.g., chemotherapy, azacitidine, or venetoclax) is based on leveraging distinct mechanisms of action to achieve both cytotoxic debulking and differentiation of leukaemic cells. Interestingly, these combination treatments may even help mitigate the risk of differentiation syndrome [ 70 ], which is a commonly occurring drug‐related adverse event associated with menin inhibitor monotherapies (Table 2 ). While there is a logical basis for combining menin inhibition with current standard‐of‐care approaches, additional preclinical work is required to better understand the mechanistic basis of and optimise any additive/synergistic effects. Further research should explore the optimal sequencing of these double, triple and even quadruple combination treatments (including other targeted therapies i.e. FLT3 and MEK inhibitors): for instance, whether the agents should be given concurrently or sequentially, and whether certain components could be dropped over time. Comparative evaluation of differentiation syndrome rates, myelosuppression, QTc impact, minimum residual disease clearance and response durability will be crucial going forward. These evolving strategies should continue to expand our understanding of other resistance pathways and hopefully pave the way for novel or improved therapeutic approaches to refine treatment paradigms and enhance remission rates.

Clinical positioning of menin inhibitors

Menin inhibition is one of the latest additions to the growing arsenal of targeted AML treatments, particularly for subsets of patients harbouring KMT2A rearrangements or NPM1 mutations. The precise mechanism underpinning the reliance of this latter AML subtype on the menin‐KMT2A interaction is unclear but is presumably due to a loss of nuclear function (as mutated NPM1 persists in the cytoplasm), culminating in upregulation of HOX gene expression which in turn drives leukemogenesis [ 71 , 72 ]. Regardless, the regulatory pathway for KMT2A and NPM1 ‐mutated AML subtypes is more clearly defined and is probably why commercial development efforts have been focused on these patient cohorts. However, there is a broader spectrum of patients (e.g. those with NUP98 or NUP214 rearrangements, UBTF tandem duplications and other HOX ‐mediated leukaemias) who could benefit from menin inhibition as the field evolves, due to the dependency of their leukaemic cells on the menin‐KMT2A interaction.

Menin inhibitors are currently undergoing investigation as monotherapies or in combination with intensive chemotherapies (typically for younger, fit patients) and more targeted treatment regimens (for older and/or unfit patients). Clinical exploration has centred on menin inhibition within the R/R AML setting (Table 2 ), and this is further underscored by the FDA's approval of revumenib for KMT2Ar R/R AML in patients aged 1 year or older [ 48 ]. However, there is growing interest in expanding into frontline regimens for newly diagnosed AML and potentially utilising menin inhibitors as maintenance therapy, even after allogeneic stem cell transplantation, where appropriate. Additionally, the effectiveness of menin inhibitors in paediatric patients is also being explored via the extension of adult study criteria to include younger individuals in clinical trials (bolded trials in Table 2 ). This will hopefully accelerate the establishment of safe and effective paediatric dosages, potentially in combination with appropriate multi‐agent chemotherapy. Collectively, the data from early‐stage clinical trials is promising and demonstrates proof‐of‐concept; however, it is clear that larger, randomised Phase III studies are necessary for validation. Furthermore, there remains a lack of long‐term data on the durability of clinical responses, the potential for late‐emerging toxicities and overall survival benefits [ 73 ].

Outlook and future considerations

The expansion of targeted treatment options for AML offers improved efficacy and fewer toxicities, culminating in a greater quality of life for patients. Menin inhibition will undoubtedly reshape the treatment paradigm for patients with KMT2A r and other menin‐sensitive genetic alterations that were beyond the scope of this review, including: NPM1 mutations, NUP98 and NUP214 rearrangements, and UBTF tandem duplications. To help achieve this, the creation of a predictive/pharmacodynamic biomarker assay that is capable of reliably detecting HOX gene expression (or a characteristic gene signature based on menin‐KMT2A binding motifs) would be ideal for: (a) identifying and expanding into a larger subset of patients that may benefit from menin inhibition; (b) predicting the responses of a patient to different menin inhibitors ex vivo to better inform and tailor treatment regimens; and (c) helping to monitor treatment responses (which should also be supplemented with standardised prospective monitoring of MEN1 mutation status). Furthermore, while the emergence of drug resistance is inevitable, ongoing research into combining menin inhibitors with other targeted therapies that could prevent and/or overcome acquired resistance is encouraging. However, realising the full potential of menin inhibition within the paediatric/childhood setting of AML will require global co‐operation. Securing ethical approval for trial initiation, overcoming patient recruitment and enrolment hurdles, sharing data and resources, as well as forging collaborative partnerships between industry, academic institutions, government agencies and clinicians are all vital components for accelerating progress and ultimately ensuring broad access to this promising therapy for all children and adolescents with KMT2Ar AML.

Conflicts of interest

LER and KML have no conflicts of interest to declare. GG received an honorarium from Novartis, GSK. GG also reports financial support in the form of an Education Support/Travel award from Novartis.

Author contributions

Drafting of the manuscript and articulation of the primary content were undertaken by LER. Revisions to enhance the intellectual content and ensure accuracy were performed by LER, GG and KML. All authors have reviewed and approved the manuscript in its final form.

Acknowledgements

Research in the laboratories of KML and GG is funded, in part, by Leukaemia and Lymphoma Northern Ireland; LER is supported by a research grant from Leukaemia and Lymphoma Northern Ireland (R2060CNR).

References

1 Aung MMK , Mills ML , Bittencourt‐Silvestre J & Keeshan K ( 2021 ) Insights into the molecular profiles of adult and paediatric acute myeloid leukaemia . Mol Oncol 15 , 2253 – 2272 . 33421304 10.1002/1878-0261.12899 PMC8410545

2 Huls G , Woolthuis CM & Schuringa JJ ( 2025 ) Menin inhibitors in the treatment of acute myeloid leukemia . Blood 145 , 561 – 566 . 39719041 10.1182/blood.2024026232

3 Shallis RM , Wang R , Davidoff A , Ma X & Zeidan AM ( 2019 ) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges . Blood Rev 36 , 70 – 87 . 31101526 10.1016/j.blre.2019.04.005

4 Mansur MB , van Delft FW , Colman SM , Furness CL , Gibson J , Emerenciano M , Kempski H , Clappier E , Cave H , Soulier J et al . ( 2015 ) Distinctive genotypes in infants with T‐cell acute lymphoblastic leukaemia . Br J Haematol 171 , 574 – 584 . 26205622 10.1111/bjh.13613 PMC4737125

5 Bo L , Wang Y , Li Y , Wurpel JND , Huang Z & Chen ZS ( 2023 ) The battlefield of chemotherapy in pediatric cancers . Cancers 15 , 1963 . 37046624 10.3390/cancers15071963 PMC10093214

6 Bolouri H , Farrar JE , Triche T , Ries RE , Lim EL , Alonzo TA , Ma Y , Moore R , Mungall AJ , Marra MA et al . ( 2018 ) The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age‐specific mutational interactions . Nat Med 24 , 103 – 112 . 29227476 10.1038/nm.4439 PMC5907936

7 Harrison CJ , Hills RK , Moorman AV , Grimwade DJ , Hann I , Webb DK , Wheatley K , de Graaf SS , van den Berg E , Burnett AK et al . ( 2010 ) Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council treatment trials AML 10 and 12 . J Clin Oncol 28 , 2674 – 2681 . 20439644 10.1200/JCO.2009.24.8997

8 Khoury JD , Solary E , Abla O , Akkari Y , Alaggio R , Apperley JF , Bejar R , Berti E , Busque L , Chan JKC et al . ( 2022 ) The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms . Leukemia 36 , 1703 – 1719 . 35732831 10.1038/s41375-022-01613-1 PMC9252913

9 van Weelderen RE , Klein K , Harrison CJ , Jiang Y , Abrahamsson J , Arad‐Cohen N , Bart‐Delabesse E , Buldini B , De Moerloose B , Dworzak MN et al . ( 2023 ) Measurable residual disease and fusion partner independently predict survival and relapse risk in childhood KMT2A‐rearranged acute myeloid leukemia: a study by the international Berlin‐Frankfurt‐Münster study group . J Clin Oncol 41 , 2963 – 2974 . 36996387 10.1200/JCO.22.02120 PMC10414713

10 Jude CD , Climer L , Xu D , Artinger E , Fisher JK & Ernst P ( 2007 ) Unique and independent roles for MLL in adult hematopoietic stem cells and progenitors . Cell Stem Cell 1 , 324 – 337 . 18371366 10.1016/j.stem.2007.05.019 PMC2234224

11 Hsieh JJ , Cheng EH & Korsmeyer SJ ( 2003 ) Taspase1: a threonine aspartase required for cleavage of MLL and proper HOX gene expression . Cell 115 , 293 – 303 . 14636557 10.1016/s0092-8674(03)00816-x

12 Hess JL ( 2004 ) MLL: a histone methyltransferase disrupted in leukemia . Trends Mol Med 10 , 500 – 507 . 15464450 10.1016/j.molmed.2004.08.005

13 Southall SM , Wong PS , Odho Z , Roe SM & Wilson JR ( 2009 ) Structural basis for the requirement of additional factors for MLL1 SET domain activity and recognition of epigenetic marks . Mol Cell 33 , 181 – 191 . 19187761 10.1016/j.molcel.2008.12.029

14 Schraets D , Lehmann T , Dingermann T & Marschalek R ( 2003 ) MLL‐mediated transcriptional gene regulation investigated by gene expression profiling . Oncogene 22 , 3655 – 3668 . 12789274 10.1038/sj.onc.1206438

15 Chang PY , Hom RA , Musselman CA , Zhu L , Kuo A , Gozani O , Kutateladze TG & Cleary ML ( 2010 ) Binding of the MLL PHD3 finger to histone H3K4me3 is required for MLL‐dependent gene transcription . J Mol Biol 400 , 137 – 144 . 20452361 10.1016/j.jmb.2010.05.005 PMC2886590

16 Wang Z , Song J , Milne TA , Wang GG , Li H , Allis CD & Patel DJ ( 2010 ) Pro isomerization in MLL1 PHD3‐bromo cassette connects H3K4me readout to CyP33 and HDAC‐mediated repression . Cell 141 , 1183 – 1194 . 20541251 10.1016/j.cell.2010.05.016 PMC4690531

17 Meyer C , Larghero P , Lopes BA & Marschalek R ( 2024 ) The KMT2A/MLL consensus gene structure: a comprehensive update for research and diagnostic implications . Leukemia 38 , 1403 – 1406 . 38678092 10.1038/s41375-024-02261-3 PMC11147768

18 Ernst P , Fisher JK , Avery W , Wade S , Foy D & Korsmeyer SJ ( 2004 ) Definitive hematopoiesis requires the mixed‐lineage leukemia gene . Dev Cell 6 , 437 – 443 . 15030765 10.1016/s1534-5807(04)00061-9

19 Bernt KM , Zhu N , Sinha AU , Vempati S , Faber J , Krivtsov AV , Feng Z , Punt N , Daigle A , Bullinger L et al . ( 2011 ) MLL‐rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L . Cancer Cell 20 , 66 – 78 . 21741597 10.1016/j.ccr.2011.06.010 PMC3329803

20 Collins CT & Hess JL ( 2016 ) Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets . Oncogene 35 , 1090 – 1098 . 26028034 10.1038/onc.2015.174 PMC4666810

21 Forgione MO , McClure BJ , Eadie LN , Yeung DT & White DL ( 2020 ) KMT2A rearranged acute lymphoblastic leukaemia: unravelling the genomic complexity and heterogeneity of this high‐risk disease . Cancer Lett 469 , 410 – 418 . 31705930 10.1016/j.canlet.2019.11.005

22 Górecki M , Kozioł I , Kopystecka A , Budzyńska J , Zawitkowska J & Lejman M ( 2023 ) Updates in KMT2A gene rearrangement in pediatric acute lymphoblastic leukemia . Biomedicine 11 , 821 . 10.3390/biomedicines11030821 PMC10045821 36979800

23 Milne TA ( 2024 ) Chromatin and aberrant enhancer activity in KMT2A rearranged acute lymphoblastic leukemia . Curr Opin Genet Dev 86 , 102191 . 38579381 10.1016/j.gde.2024.102191 PMC7619017

24 van Weelderen RE , Harrison CJ , Klein K , Jiang Y , Abrahamsson J , Alonzo T , Aplenc R , Arad‐Cohen N , Bart‐Delabesse E , Buldini B et al . ( 2024 ) Optimized cytogenetic risk‐group stratification of KMT2A‐rearranged pediatric acute myeloid leukemia . Blood Adv 8 , 3200 – 3213 . 38621200 10.1182/bloodadvances.2023011771 PMC11225675

25 Olsen SN , Godfrey L , Healy JP , Choi YA , Kai Y , Hatton C , Perner F , Haarer EL , Nabet B , Yuan GC et al . ( 2022 ) MLL::AF9 degradation induces rapid changes in transcriptional elongation and subsequent loss of an active chromatin landscape . Mol Cell 82 , 1140 – 1155 . 35245435 10.1016/j.molcel.2022.02.013 PMC9044330

26 Mahmoudi T , Boj SF , Hatzis P , Li VS , Taouatas N , Vries RG , Teunissen H , Begthel H , Korving J , Mohammed S et al . ( 2010 ) The leukemia‐associated Mllt10/Af10‐Dot1l are Tcf4/β‐catenin coactivators essential for intestinal homeostasis . PLoS Biol 8 , e1000539 . 21103407 10.1371/journal.pbio.1000539 PMC2982801

27 Mueller D , García‐Cuéllar MP , Bach C , Buhl S , Maethner E & Slany RK ( 2009 ) Misguided transcriptional elongation causes mixed lineage leukemia . PLoS Biol 7 , e1000249 . 19956800 10.1371/journal.pbio.1000249 PMC2774266

28 Zeisig DT , Bittner CB , Zeisig BB , García‐Cuéllar MP , Hess JL & Slany RK ( 2005 ) The eleven‐nineteen‐leukemia protein ENL connects nuclear MLL fusion partners with chromatin . Oncogene 24 , 5525 – 5532 . 15856011 10.1038/sj.onc.1208699

29 Muntean AG , Giannola D , Udager AM & Hess JL ( 2008 ) The PHD fingers of MLL block MLL fusion protein‐mediated transformation . Blood 112 , 4690 – 4693 . 18796627 10.1182/blood-2008-01-134056 PMC2597135

30 Chen J , Santillan DA , Koonce M , Wei W , Luo R , Thirman MJ , Zeleznik‐Le NJ & Diaz MO ( 2008 ) Loss of MLL PHD finger 3 is necessary for MLL‐ENL‐induced hematopoietic stem cell immortalization . Cancer Res 68 , 6199 – 6207 . 18676843 10.1158/0008-5472.CAN-07-6514 PMC2734520

31 El‐Tanani M , Nsairat H , Matalka II , Lee YF , Rizzo M , Aljabali AA , Mishra V , Mishra Y , Hromić‐Jahjefendić A & Tambuwala MM ( 2024 ) The impact of the BCR‐ABL oncogene in the pathology and treatment of chronic myeloid leukemia . Pathol Res Pract 254 , 155161 . 38280275 10.1016/j.prp.2024.155161

32 Meyer C , Larghero P , Almeida Lopes B , Burmeister T , Gröger D , Sutton R , Venn NC , Cazzaniga G , Corral Abascal L , Tsaur G et al . ( 2023 ) The KMT2A recombinome of acute leukemias in 2023 . Leukemia 37 , 988 – 1005 . 37019990 10.1038/s41375-023-01877-1 PMC10169636

33 Emerenciano M , Meyer C , Mansur MB , Marschalek R & Pombo‐de‐Oliveira MS ( 2013 ) The distribution of MLL breakpoints correlates with outcome in infant acute leukaemia . Br J Haematol 161 , 224 – 236 . 23432364 10.1111/bjh.12250

34 Rössler T & Marschalek R ( 2013 ) An alternative splice process renders the MLL protein either into a transcriptional activator or repressor . Pharmazie 68 , 601 – 607 . 23923644 10.1055/s-0033-1343653

35 Wang J , Muntean AG , Wu L & Hess JL ( 2012 ) A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)‐mediated E3 ligase activity . J Biol Chem 287 , 43410 – 43416 . 23129768 10.1074/jbc.M112.423855 PMC3527928

36 Wang J , Muntean AG & Hess JL ( 2012 ) ECSASB2 mediates MLL degradation during hematopoietic differentiation . Blood 119 , 1151 – 1161 . 22174154 10.1182/blood-2011-06-362079 PMC3277351

37 Grow EJ & Wysocka J ( 2010 ) Flipping MLL1's switch one proline at a time . Cell 141 , 1108 – 1110 . 20602992 10.1016/j.cell.2010.06.013

38 Balgobind BV , Raimondi SC , Harbott J , Zimmermann M , Alonzo TA , Auvrignon A , Beverloo HB , Chang M , Creutzig U , Dworzak MN et al . ( 2009 ) Novel prognostic subgroups in childhood 11q23/MLL‐rearranged acute myeloid leukemia: results of an international retrospective study . Blood 114 , 2489 – 2496 . 19528532 10.1182/blood-2009-04-215152 PMC2927031

39 Döhner H , Wei AH , Appelbaum FR , Craddock C , DiNardo CD , Dombret H , Ebert BL , Fenaux P , Godley LA , Hasserjian RP et al . ( 2022 ) Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN . Blood 140 , 1345 – 1377 . 35797463 10.1182/blood.2022016867

40 von Neuhoff C , Reinhardt D , Sander A , Zimmermann M , Bradtke J , Betts DR , Zemanova Z , Stary J , Bourquin JP , Haas OA et al . ( 2010 ) Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML‐BFM 98 . J Clin Oncol 28 , 2682 – 2689 . 20439630 10.1200/JCO.2009.25.6321

41 Marschalek R ( 2016 ) Systematic classification of mixed‐lineage leukemia fusion partners predicts additional cancer pathways . Ann Lab Med 36 , 85 – 100 . 26709255 10.3343/alm.2016.36.2.85 PMC4713862

42 Kundu A , Kowarz E & Marschalek R ( 2021 ) The role of reciprocal fusions in MLL‐r acute leukemia: studying the chromosomal translocation t(6;11) . Oncogene 40 , 5902 – 5912 . 34354240 10.1038/s41388-021-01983-3 PMC8497272

43 Matkar S , Thiel A & Hua X ( 2013 ) Menin: a scaffold protein that controls gene expression and cell signaling . Trends Biochem Sci 38 , 394 – 402 . 23850066 10.1016/j.tibs.2013.05.005 PMC3741089

44 Chandrasekharappa SC , Guru SC , Manickam P , Olufemi SE , Collins FS , Emmert‐Buck MR , Debelenko LV , Zhuang Z , Lubensky IA , Liotta LA et al . ( 1997 ) Positional cloning of the gene for multiple endocrine neoplasia‐type 1 . Science 276 , 404 – 407 . 9103196 10.1126/science.276.5311.404

45 Lemmens I , de Van Ven WJ , Kas K , Zhang CX , Giraud S , Wautot V , Buisson N , De Witte K , Salandre J , Lenoir G et al . ( 1997 ) Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1 . Hum Mol Genet 6 , 1177 – 1183 . 9215690 10.1093/hmg/6.7.1177

46 Thiel AT , Huang J , Lei M & Hua X ( 2012 ) Menin as a hub controlling mixed lineage leukemia . BioEssays 34 , 771 – 780 . 22829075 10.1002/bies.201200007 PMC3536020

47 Yokoyama A , Somervaille TC , Smith KS , Rozenblatt‐Rosen O , Meyerson M & Cleary ML ( 2005 ) The menin tumor suppressor protein is an essential oncogenic cofactor for MLL‐associated leukemogenesis . Cell 123 , 207 – 218 . 16239140 10.1016/j.cell.2005.09.025

48 Mullard A ( 2025 ) FDA approves first menin inhibitor, for acute leukaemia . Nat Rev Drug Discov 24 , 7 . 10.1038/d41573-024-00198-x 39627423

49 Shi A , Murai MJ , He S , Lund G , Hartley T , Purohit T , Reddy G , Chruszcz M , Grembecka J & Cierpicki T ( 2012 ) Structural insights into inhibition of the bivalent menin‐MLL interaction by small molecules in leukemia . Blood 120 , 4461 – 4469 . 22936661 10.1182/blood-2012-05-429274 PMC3512226

50 Borkin D , He S , Miao H , Kempinska K , Pollock J , Chase J , Purohit T , Malik B , Zhao T , Wang J et al . ( 2015 ) Pharmacologic inhibition of the Menin‐MLL interaction blocks progression of MLL leukemia in vivo . Cancer Cell 27 , 589 – 602 . 25817203 10.1016/j.ccell.2015.02.016 PMC4415852

51 Wu Y , Doepner M , Hojnacki T , Feng Z , Katona BW , He X , Ma J , Cao Y , Busino L , Zhou F et al . ( 2019 ) Disruption of the menin‐MLL interaction triggers menin protein degradation via ubiquitin‐proteasome pathway . Am J Cancer Res 9 , 1682 – 1694 . 31497350 PMC6726985

52 Sparbier CE , Gillespie A , Gomez J , Kumari N , Motazedian A , Chan KL , Bell CC , Gilan O , Chan YC , Popp S et al . ( 2023 ) Targeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genes . Nat Cell Biol 25 , 258 – 272 . 36635503 10.1038/s41556-022-01056-x PMC7614190

53 Hogeling SM , Lê DM , La Rose N , Kwon MC , Wierenga ATJ , den Van Heuvel FAJ , den Van Boom V , Kuchnio A , Philippar U , Huls G et al . ( 2024 ) Bleximenib, the novel menin‐KMT2A inhibitor JNJ‐75276617, impairs long‐term proliferation and immune evasion in acute myeloid leukemia . Haematologica 110 , 1278 – 1291 . 39704147 10.3324/haematol.2024.285616 PMC12130779

54 Issa GC , Ravandi F , DiNardo CD , Jabbour E , Kantarjian HM & Andreeff M ( 2021 ) Therapeutic implications of menin inhibition in acute leukemias . Leukemia 35 , 2482 – 2495 . 34131281 10.1038/s41375-021-01309-y

55 Cuglievan B , Kantarjian H , Rubnitz JE , Cooper TM , Zwaan CM , Pollard JA , DiNardo CD , Kadia TM , Guest E , Short NJ et al . ( 2024 ) Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community . Leukemia 38 , 2073 – 2084 . 39179671 10.1038/s41375-024-02368-7 PMC11436367

56 Perner F , Stein EM , Wenge DV , Singh S , Kim J , Apazidis A , Rahnamoun H , Anand D , Marinaccio C , Hatton C et al . ( 2023 ) MEN1 mutations mediate clinical resistance to menin inhibition . Nature 615 , 913 – 919 . 36922589 10.1038/s41586-023-05755-9 PMC10157896

57 Ray J , Clegg B , Grembecka J & Cierpicki T ( 2024 ) Drug‐resistant menin variants retain high binding affinity and interactions with MLL1 . J Biol Chem 300 , 107777 . 39276940 10.1016/j.jbc.2024.107777 PMC11490872

58 Zhou X , Zhang L , Aryal S , Veasey V , Tajik A , Restelli C , Moreira S , Zhang P , Zhang Y , Hope KJ et al . ( 2024 ) Epigenetic regulation of noncanonical menin targets modulates menin inhibitor response in acute myeloid leukemia . Blood 144 , 2018 – 2032 . 39158067 10.1182/blood.2023023644 PMC11561541

59 Soto‐Feliciano YM , Sánchez‐Rivera FJ , Perner F , Barrows DW , Kastenhuber ER , Ho YJ , Carroll T , Xiong Y , Anand D , Soshnev AA et al . ( 2023 ) A molecular switch between mammalian MLL complexes dictates response to Menin‐MLL inhibition . Cancer Discov 13 , 146 – 169 . 36264143 10.1158/2159-8290.CD-22-0416 PMC9827117

60 Mahdavi L , Goodrow H , Xie H , Lenard A , Alikarami F , Riedel SS , Tasian SK , Wertheim G , Skuli S , Carroll M et al . ( 2023 ) Transcriptomic without clinical response to Menin inhibition as a mechanism of upfront resistance in samples from Mutliply relapsed patients with KMT2A‐rearranged leukemia . Blood 142 , 4166 .

61 Mahdavi L , Goodrow H , Alikarami F , Lenard A , Riedel SS , Libbrecht C , Bowser I , Tasian SK , Falkenstein CD , Manning B et al . ( 2024 ) Upfront menin‐inhibitor resistance in multiply pretreated Leukemias . bioRxiv . 2023.03.16.532874. 10.1016/j.exphem.2025.105268 41027490

62 Arthur NBJ , Christensen KA , Mannino K , Ruzinova MB , Kumar A , Gruszczynska A , Day RB , Erdmann‐Gilmore P , Mi Y , Sprung R et al . ( 2024 ) Missense mutations in Myc box I influence nucleocytoplasmic transport to promote leukemogenesis . Clin Cancer Res 30 , 3622 – 3639 . 38848040 10.1158/1078-0432.CCR-24-0926 PMC11326984

63 Pan XN , Chen JJ , Wang LX , Xiao RZ , Liu LL , Fang ZG , Liu Q , Long ZJ & Lin DJ ( 2014 ) Inhibition of c‐Myc overcomes cytotoxic drug resistance in acute myeloid leukemia cells by promoting differentiation . PLoS One 9 , e105381 . 25127121 10.1371/journal.pone.0105381 PMC4134294

64 Kwon MC , Thuring JW , Querolle O , Dai X , Verhulst T , Pande V , Marien A , Goffin D , Wenge DV , Yue H et al . ( 2024 ) Preclinical efficacy of the potent, selective menin‐KMT2A inhibitor JNJ‐75276617 (bleximenib) in KMT2A‐ and NPM1‐altered leukemias . Blood 144 , 1206 – 1220 . 38905635 10.1182/blood.2023022480 PMC11419783

65 Hertlein EA‐A , Lerma J , Furby C , Long M , Johnstone M , Orry A , Lam P , Abagyan R , Khvat A , Savchuk N et al . ( 2024 ) The novel menin inhibitor ZE63‐0302 has an impressive safety profile and unique chemistry that suggests improved efficacy against resistance mutations . Paper Presented at The EHA2024: Madrid, Spain.

66 Hernández‐Sánchez A , González T , Sobas M , Sträng E , Castellani G , Abáigar M , Valk PJM , Villaverde Ramiro Á , Benner A , Metzeler KH et al . ( 2024 ) Rearrangements involving 11q23.3/KMT2A in adult AML: mutational landscape and prognostic implications ‐ a HARMONY study . Leukemia 38 , 1929 – 1937 . 38965370 10.1038/s41375-024-02333-4 PMC11347382

67 Iyoda S , Yoshida K , Shoji K , Ito N , Tanaka M , Nannya Y , Yamato G , Tsujimoto S , Shiba N , Hayashi Y et al . ( 2024 ) KRAS G12 mutations as adverse prognostic factors in KMT2A‐rearranged acute myeloid leukemia . Leukemia 38 , 1609 – 1612 . 38632314 10.1038/s41375-024-02244-4

68 Hyrenius‐Wittsten A , Pilheden M , Sturesson H , Hansson J , Walsh MP , Song G , Kazi JU , Liu J , Ramakrishan R , Garcia‐Ruiz C et al . ( 2018 ) De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A‐rearranged leukemia . Nat Commun 9 , 1770 . 29720585 10.1038/s41467-018-04180-1 PMC5932012

69 Scheidegger N , Alexe G , Khalid D , Ries RE , Wang J , Alonzo TA , Perry J , Armstrong SA , Meshinchi S , Pikman Y et al . ( 2023 ) Combining Menin and MEK inhibition to target poor prognostic KMT2A‐rearranged RAS pathway‐mutant acute leukemia . Blood 142 , 166 .

70 Canichella M , Papayannidis C , Mazzone C & de Fabritiis P ( 2025 ) Therapeutic implications of Menin inhibitors in the treatment of acute leukemia: A Critical Review . Diseases 13 , 227 . 40710017 10.3390/diseases13070227 PMC12294120

71 Spencer DH , Young MA , Lamprecht TL , Helton NM , Fulton R , O'Laughlin M , Fronick C , Magrini V , Demeter RT , Miller CA et al . ( 2015 ) Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells . Leukemia 29 , 1279 – 1289 . 25600023 10.1038/leu.2015.6 PMC4456213

72 Alcalay M , Tiacci E , Bergomas R , Bigerna B , Venturini E , Minardi SP , Meani N , Diverio D , Bernard L , Tizzoni L et al . ( 2005 ) Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up‐regulation of genes involved in stem‐cell maintenance . Blood 106 , 899 – 902 . 15831697 10.1182/blood-2005-02-0560

73 Zehtabcheh S , Soleimani Samarkhazan H , Asadi M , Zabihi M , Parkhideh S & Mohammadi MH ( 2025 ) Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies . Biomark Res 13 , 73 . 40361241 10.1186/s40364-025-00786-y PMC12077025

74 Grembecka J , He S , Shi A , Purohit T , Muntean AG , Sorenson RJ , Showalter HD , Murai MJ , Belcher AM , Hartley T et al . ( 2012 ) Menin‐MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia . Nat Chem Biol 8 , 277 – 284 . 22286128 10.1038/nchembio.773 PMC3401603

75 He S , Senter TJ , Pollock J , Han C , Upadhyay SK , Purohit T , Gogliotti RD , Lindsley CW , Cierpicki T , Stauffer SR et al . ( 2014 ) High‐affinity small‐molecule inhibitors of the menin‐mixed lineage leukemia (MLL) interaction closely mimic a natural protein‐protein interaction . J Med Chem 57 , 1543 – 1556 . 24472025 10.1021/jm401868d PMC3983337

76 Borkin D , Pollock J , Kempinska K , Purohit T , Li X , Wen B , Zhao T , Miao H , Shukla S , He M et al . ( 2016 ) Property focused structure‐based optimization of small molecule inhibitors of the protein‐protein interaction between Menin and mixed lineage leukemia (MLL) . J Med Chem 59 , 892 – 913 . 26744767 10.1021/acs.jmedchem.5b01305 PMC5092235

77 Borkin D , Klossowski S , Pollock J , Miao H , Linhares BM , Kempinska K , Jin Z , Purohit T , Wen B , He M et al . ( 2018 ) Complexity of blocking bivalent protein‐protein interactions: development of a highly potent inhibitor of the Menin‐mixed‐lineage leukemia interaction . J Med Chem 61 , 4832 – 4850 . 29738674 10.1021/acs.jmedchem.8b00071 PMC7029623

78 Klossowski S , Miao H , Kempinska K , Wu T , Purohit T , Kim E , Linhares BM , Chen D , Jih G , Perkey E et al . ( 2020 ) Menin inhibitor MI‐3454 induces remission in MLL1‐rearranged and NPM1‐mutated models of leukemia . J Clin Invest 130 , 981 – 997 . 31855575 10.1172/JCI129126 PMC6994154

79 Fiskus W , Daver N , Boettcher S , Mill CP , Sasaki K , Birdwell CE , Davis JA , Das K , Takahashi K , Kadia TM et al . ( 2022 ) Activity of menin inhibitor ziftomenib (KO‐539) as monotherapy or in combinations against AML cells with MLL1 rearrangement or mutant NPM1 . Leukemia 36 , 2729 – 2733 . 36151141 10.1038/s41375-022-01707-w PMC9613474

80 Krivtsov AV , Evans K , Gadrey JY , Eschle BK , Hatton C , Uckelmann HJ , Ross KN , Perner F , Olsen SN , Pritchard T et al . ( 2019 ) A Menin‐MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL‐rearranged leukemia . Cancer Cell 36 , 660 – 673.e11 . 31821784 10.1016/j.ccell.2019.11.001 PMC7227117

81 Issa GC , Aldoss I , DiPersio J , Cuglievan B , Stone R , Arellano M , Thirman MJ , Patel MR , Dickens DS , Shenoy S et al . ( 2023 ) The menin inhibitor revumenib in KMT2A‐rearranged or NPM1‐mutant leukaemia . Nature 615 , 920 – 924 . 36922593 10.1038/s41586-023-05812-3 PMC10060155

82 Kwon MC , Querolle O , Dai X , Thuring JW , Verhulst T , Marien A , Goffin D , Cai W , Keersmaekers V , Eyassu F et al . ( 2022 ) Pharmacological characterization of JNJ‐75276617, a Menin‐KMT2A inhibitor, As targeted treatment for KMT2A‐altered and NPM1‐mutant acute leukemia . Blood 140 , 5928 – 5929 .

83 Eguchi K , Shimizu T , Kato D , Furuta Y , Kamioka S , Ban H , Ymamoto S , Yokoyama A & Kitabayashi I ( 2021 ) Preclinical evaluation of a novel orally bioavailable Menin‐MLL interaction inhibitor, DSP‐5336, for the treatment of acute leukemia patients with MLL‐rearrangement or NPM1 mutation . Blood 138 , 3339 .

84 Numata M , Haginoya N , Shiroishi M , Hirata T , Sato‐Otsubo A , Yoshikawa K , Takata Y , Nagase R , Kashimoto Y , Suzuki M et al . ( 2023 ) A novel Menin‐MLL1 inhibitor, DS‐1594a, prevents the progression of acute leukemia with rearranged MLL1 or mutated NPM1 . Cancer Cell Int 23 , 36 . 36841758 10.1186/s12935-023-02877-y PMC9960487

85 Wu D , Wang Y , Chen S , Li Y , Huang R , Ren J , Guo X , Li Y , Sun M , Wei X et al . ( 2024 ) A first‐in‐human phase 1/2 study of the Menin‐KMT2A(MLL1) inhibitor BN104 in adult patients with relapsed or refractory acute leukemia . Blood 144 , 2879 .

86 Lancet J , Ravandi F , Montesinos P , Barrientos JC , Badar T , Alegre A , Bashey A , Bergua Burgues JM , Brunetti L , Curran EK et al . ( 2023 ) Covalent menin inhibitor Bmf‐219 in patients with relapsed or refractory (R/R) acute leukemia (AL): preliminary phase 1 data from the Covalent‐101 study . Blood 142 , 2916 .

87 Brzezinka K , Nevedomskaya E , Lesche R , Haegebarth A , Ter Laak A , Fernández‐Montalván AE , Eberspaecher U , Werbeck ND , Moenning U , Siegel S et al . ( 2020 ) Characterization of the Menin‐MLL interaction as therapeutic cancer target . Cancers 12 , 201 . 31947537 10.3390/cancers12010201 PMC7016952

88 Cheng M , Ge L , Gao Z , Zhong Z , Jiang A , Zhang W , Hu J , Jiang S , Li N , Yang N et al . ( 2024 ) Abstract 2113: HMPL‐506, a novel, highly potent and differentiated menin‐MLL inhibitor for the treatment of MLL‐rearrangedand NPM1mutant acute leukemia in preclinical models . Cancer Res 84 , 2113 .

89 Wang ES , Issa GC , Erba HP , Altman JK , Montesinos P , DeBotton S , Walter RB , Pettit K , Savona MR , Shah MV et al . ( 2024 ) Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET‐001): a multicentre, open‐label, multi‐cohort, phase 1 trial . Lancet Oncol 25 , 1310 – 1324 . 39362248 10.1016/S1470-2045(24)00386-3

90 Zeidan AM , Wang ES , Issa GC , Erba H , Altman JK , Balasubramanian SK , Strickland SA , Roboz GJ , Schiller GJ , McMahon CM et al . ( 2024 ) Ziftomenib combined with intensive induction (7 + 3) in newly diagnosed NPM1‐m or KMT2A‐r acute myeloid Leukemia: interim phase 1a results from KOMET‐007 . Blood 144 , 214 .

91 Fathi AT , Issa GC , Wang ES , Erba H , Altman JK , Balasubramanian SK , Roboz GJ , Schiller GJ , McMahon CM , Palmisiano ND et al . ( 2024 ) Ziftomenib combined with Venetoclax/Azacitidine in relapsed/refractory NPM1‐m or KMT2A‐r acute myeloid leukemia: interim phase 1a results from KOMET‐007 . Blood 144 , 2880 .

92 Goldberg AD , Corum D , Ahsan J , Nie K , Kozlek T , Leoni M & Dale S ( 2023 ) Komet‐008: a phase 1 study to determine the safety and tolerability of Ziftomenib combinations for the treatment of KMT2A‐rearranged or NPM1‐mutant relapsed/refractory acute myeloid Leukemia . Blood 142 , 1553 .

93 Salzer E , Stutterheim J , Cuglievan B , Tomkinson BE , Leoni M , Van Tinteren H , Huitema ADR , Willemse M , Nichols GL , Bautista F et al . ( 2024 ) APAL2020K/ITCC‐101: a phase I trial of the menin inhibitor Ziftomenib in combination with chemotherapy in children with relapsed/refractory KMT2A‐rearranged, NUP98‐rearranged, or NPM1‐mutant acute Leukemia . Blood 144 , 4265.3 .

94 Kura O , ed. ( 2025 ) Frontline Ziftomenib in NPM1‐mutated or KMT2A‐rearranged acute myeloid Leukemia in patients not eligible for intensive induction or other therapy .

95 Kura Oncology I , ed. ( 2024 ) A phase I study investigating the combination of the menin inhibitor Ziftomenib with Venetoclax and Gemtuzumab in pediatric patients with acute myeloid Leukemia .

96 Issa GC , Aldoss I , Thirman MJ , DiPersio J , Arellano M , Blachly JS , Mannis GN , Perl A , Dickens DS , McMahon CM et al . ( 2025 ) Menin inhibition with Revumenib for KMT2A‐rearranged relapsed or refractory acute Leukemia (AUGMENT‐101) . J Clin Oncol 43 , 75 – 84 . 39121437 10.1200/JCO.24.00826 PMC11687943

97 Shukla N , Tasian SK , Breese E , Schafer E , Dipersio J , Issa GC , Silverman LB , Stieglitz E , Pollard J , Assouline S et al . ( 2024 ) Safety and activity of Revumenib in combination with Fludarabine/Cytarabine (FLA) in patients with relapsed/refractory acute Leukemias . Paper Presented at the EHA2024 Congress: Madrid, Spain.

98 ClinicalTrials.gov [ NCT05886049 ] A phase 1b study of menin inhibitor SNDX‐5613 in combination with Daunorubicin and Cytarabine in newly diagnosed patients with acute myeloid Leukemia and NPM1 mutated/FLT3 wildtype or MLL/KMT2A REARRANGED Disease . Registered 1 June 2023.

99 Syndax P , ed. ( 2023 ) A phase 1 study of Revumenib, Azacitidine, and Venetoclax in pediatric and young adult patients with refractory or relapsed acute myeloid Leukemia .

100 Issa GC , Cuglievan B , Daver N , DiNardo CD , Farhat A , Short NJ , McCall D , Pike A , Tan S , Kammerer B et al . ( 2024 ) Phase I/II study of the all‐oral combination of Revumenib (SNDX‐5613) with decitabine/Cedazuridine (ASTX727) and Venetoclax (SAVE) in R/R AML . Blood 144 , 216 .38648571

101 National Cancer I ( 2024 ) A phase I Study of SNDX 5613 (Revumenib) as post‐transplant maintenance after allogeneic hematopoietic cell transplant in patients with KMT2A‐rearranged or NPM1‐mutated acute Leukemia .

102 Zeidner JW , Lin TL , Curran E , Koenig K , Stock W , Odenike O , Madanat Y , Swords R , Baer M , Stein E et al . ( 2025 ) Azacitidine, Venetoclax, and Revumenib for newly diagnosed older adults with acute myeloid Leukemia (AML) and NPM1 mutation OR KMT2A rearrangement: updated results from the beat AML consortium . Paper presented at the EHA2025: Madrid, Spain.

103 ClinicalTrials.gov [ NCT06222580 ] Safety and efficacy of dual menin and FLT3 inhibition in patients with Relapsed/Refractory FLT3‐ mutated acute myeloid leukemia containing a concurrent MLL‐rearrangement or NPM1 mutation: A phase I (Ph I) study of SNDX‐5613 + Gilteritinib . Registered 16 January 2024.

104 Jabbour E , Searle E , Abdul‐Hay M , Abedin S , Aldoss I , Alfonso Piérola A , Alonso‐Dominguez JM , Chevallier P , Cost C , Daskalakis N et al . ( 2023 ) A first‐in‐human phase 1 study of the Menin‐KMT2A (MLL1) inhibitor JNJ‐75276617 in adult patients with relapsed/refractory acute leukemia harboring KMT2A or NPM1 alterations . Blood 142 , 57 .

105 ClinicalTrials.gov [ NCT06852222 ] A phase 3 randomized, double‐blind, placebo‐controlled, study of Bleximenib, Venetoclax and Azacitidine for the treatment of participants with newly diagnosed acute myeloid leukemia harboring KMT2A rearrangements or NPM1 mutations who are ineligible for intensive chemotherapy . Registered 25 February 2025.

106 Recher C , O'Nions J , Aldoss I , Pierola AA , Allred A , Alonso‐Dominguez JM , Barreyro L , Bories P , Curtis M , Daskalakis N et al . ( 2024 ) Phase 1b study of Menin‐KMT2A inhibitor Bleximenib in combination with intensive chemotherapy in newly diagnosed acute myeloid leukemia with KMT2Ar or NPM1 alterations . Blood 144 , 215 .

107 Wei AH , Garciaz S , Aldoss I , Piérola AA , Allred A , Dominguez JMA , Barreyro A , Bories P , Daskalakis N , Porta MGD et al . ( 2025 ) RP2D determination of bleximenib in combination with VEN + AZA: phase 1B study in ND & R/R AML with KMT2A/NPM1 alterations . Paper Presented at the EHA2025: Madrid, Spain.

108 Zeidner JF , Yuda J , Watts JM , Levis MJ , Erba HP , Fukushima K , Shima T , Palmisiano ND , Wang ES , Borate U et al . ( 2024 ) Phase 1 results: first‐in‐human phase 1/2 study of the Menin‐MLL inhibitor Enzomenib (DSP‐5336) in patients with relapsed or refractory acute leukemia . Blood 144 , 213 .

109 ClinicalTrials.gov [ NCT04752163 ] An open‐label phase 1/2 multi‐arm study of DS‐1594b as a single‐agent and in combination with Azacitidine and Venetoclax or mini‐HCVD for the treatment of patients with acute myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) . Registered 8 February 2021.

110 ClinicalTrials.gov [ NCT06746519 ] A phase I/II, multicenter, open label clinical study evaluating the safety, pharmacokinetics, and efficacy of the combination of the menin inhibitor BN104 for the treatment of patients with acute myeloid leukemia . Registered 19 December 2024.

111 ClinicalTrials.gov [ NCT06780124 ] An exploratory randomized, double‐blind, placebo‐controlled, first‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple ascending doses of ZE63‐0302 in healthy volunteers . Registered 16 January 2025.

112 Bourgeois W , Cutler JA , Aubrey BJ , Wenge DV , Perner F , Martucci C , Henrich JA , Klega K , Nowak RP , Donovan KA et al . ( 2024 ) Mezigdomide is effective alone and in combination with menin inhibition in preclinical models of KMT2A‐r and NPM1c AML . Blood 143 , 1513 – 1527 . 38096371 10.1182/blood.2023021105 PMC11033588

113 Zhu W , Ding Y , Huang W , Guo N , Ren Q , Wang N & Ma X ( 2024 ) Synergistic effects of the KDM4C inhibitor SD70 and the menin inhibitor MI‐503 against MLL::AF9‐driven acute myeloid leukaemia . Br J Haematol 205 , 568 – 579 . 38877874 10.1111/bjh.19591

114 Fiskus W , Mill CP , Birdwell C , Davis JA , Das K , Boettcher S , Kadia TM , DiNardo CD , Takahashi K , Loghavi S et al . ( 2023 ) Targeting of epigenetic co‐dependencies enhances anti‐AML efficacy of menin inhibitor in AML with MLL1‐r or mutant NPM1 . Blood Cancer J 13 , 53 . 37055414 10.1038/s41408-023-00826-6 PMC10102188

115 Rausch J , Dzama MM , Dolgikh N , Stiller HL , Bohl SR , Lahrmann C , Kunz K , Kessler L , Echchannaoui H , Chen CW et al . ( 2023 ) Menin inhibitor ziftomenib (KO‐539) synergizes with drugs targeting chromatin regulation or apoptosis and sensitizes acute myeloid leukemia with MLL rearrangement or NPM1 mutation to venetoclax . Haematologica 108 , 2837 – 2843 . 37102614 10.3324/haematol.2022.282160 PMC10543165

116 Fiskus W , Piel J , Collins M , Hentemann M , Cuglievan B , Mill CP , Birdwell CE , Das K , Davis JA , Hou H et al . ( 2024 ) BRG1/BRM inhibitor targets AML stem cells and exerts superior preclinical efficacy combined with BET or menin inhibitor . Blood 143 , 2059 – 2072 . 38437498 10.1182/blood.2023022832 PMC11830987

117 Dafflon C , Craig VJ , Méreau H , Gräsel J , Schacher Engstler B , Hoffman G , Nigsch F , Gaulis S , Barys L , Ito M et al . ( 2017 ) Complementary activities of DOT1L and menin inhibitors in MLL‐rearranged leukemia . Leukemia 31 , 1269 – 1277 . 27840424 10.1038/leu.2016.327

118 Shi X , Li M , Liu Z , Tiessen J , Li Y , Zhou J , Zhu Y , Mahesula S , Ding Q , Tan L et al . ( 2025 ) Guanine nucleotide biosynthesis blockade impairs MLL complex formation and sensitizes leukemias to menin inhibition . Nat Commun 16 , 2641 . 40102405 10.1038/s41467-025-57544-9 PMC11920272

119 Fiskus W , Boettcher S , Daver N , Mill CP , Sasaki K , Birdwell CE , Davis JA , Takahashi K , Kadia TM , DiNardo CD et al . ( 2022 ) Effective menin inhibitor‐based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) . Blood Cancer J 12 , 5 . 35017466 10.1038/s41408-021-00603-3 PMC8752621